These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24982069)

  • 21. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
    Roilides E; Ashouri N; Bradley JS; Johnson MG; Lonchar J; Su FH; Huntington JA; Popejoy MW; Bensaci M; De Anda C; Rhee EG; Bruno CJ
    Pediatr Infect Dis J; 2023 Apr; 42(4):292-298. PubMed ID: 36689671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
    Kubo S; Shinkawa H; Tanaka S; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Shirai D; Okada T; Tani N; Ishizawa T
    J Infect Chemother; 2023 Sep; 29(9):895-899. PubMed ID: 37276996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ; Chahine EB; Cogan P; Fete M
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
    Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
    Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
    Kong W; Deng T; Li S; Shu Y; Wu Y
    BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
    Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
    Martin-Loeches I; Timsit JF; Kollef MH; Wunderink RG; Shime N; Nováček M; Kivistik Ü; Réa-Neto Á; Bruno CJ; Huntington JA; Lin G; Jensen EH; Motyl M; Yu B; Gates D; Butterton JR; Rhee EG
    J Antimicrob Chemother; 2022 Mar; 77(4):1166-1177. PubMed ID: 35022730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M; Righi E
    Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
    Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
    Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.
    Cheng IL; Chen YH; Lai CC; Tang HJ
    Int J Antimicrob Agents; 2020 Feb; 55(2):105858. PubMed ID: 31786332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
    Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.
    Ouyang W; Xue H; Chen Y; Gao W; Li X; Wei J; Wen Z
    Int J Antimicrob Agents; 2016 Mar; 47(3):210-6. PubMed ID: 26899413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.